Concepedia

Michael Berger

MB

Statistics

Publications

13

Citations

470

H-Index

12

Active since

2000

Affiliations

The Ohio State University(Current)

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

The Ohio State University Wexner Medical Center

The University of Texas MD Anderson Cancer Center

Michael Berger is an author at The Ohio State University specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2000–2023

13

Publications

13

Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

Maryam B. Lustberg, Priya Balasubramanian, Brandon Miller et al. · Breast Cancer Research · 2014 · 123 citations · Full text

, , +14

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab

Hannah Dzimitrowicz, Michael Berger, Craig Vargo et al. · Journal of Clinical Oncology · 2016 · 84 citations · Full text

, , +17

Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer

Jonathan Wilkie, M. Alexandra Schickli, Michael Berger et al. · Clinical Breast Cancer · 2019 · 47 citations

, , +16

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review

Ming Poi, Michael Berger, Maryam B. Lustberg et al. · Supportive Care in Cancer · 2013 · 36 citations

, , +17

Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

Michael Berger, Craig Vargo, M J Vincent et al. · Supportive Care in Cancer · 2014 · 28 citations · Full text

, , +14

1–5 of 13